LivaNova PLC (NASDAQ:LIVN) Files An 8-K Other EventsItem 8.01 Other Events.
On October 16, 2018, the Compensation Committee of the Board of Directors of LivaNova Plc (the “Company”) approved an amended procedure to facilitate the periodic issuance of equity awards. Until further notice, the Compensation Committee will approve all equity awards with an effective date of March 30 (rather than March 15), June 15, September 15 or December 15 of each year (each, a “Quarterly Grant Date”). Under the procedure, the Compensation Committee may meet on or prior to the Quarterly Grant Date without regard as to the Company’s possession or not of material non-public information and approve equity awards with an effective date on the Quarterly Grant Date. The share price in respect of any such award will be the most recent closing price of an ordinary share of the Company’s stock on the NASDAQ Stock Market as of the Quarterly Grant Date.
About LivaNova PLC (NASDAQ:LIVN)
LivaNova PLC is a medical technology company. The Company operates through three segments: Cardiac Surgery, Cardiac Rhythm Management (CRM) and Neuromodulation. The Cardiac Surgery business unit is engaged in the development, production and sale of cardiovascular surgery products, including oxygenators, heart-lung machines, perfusion tubing systems and systems for autotransfusion and autologous blood washing. The CRM business unit develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failure. CRM offers products, including leads and delivery systems, and information systems. The Neuromodulation business unit designs, develops and markets neuromodulation-based medical devices for the treatment of epilepsy and depression. Through the Neuromodulation business unit, the Company markets its implantable VNS Therapy systems that deliver vagus nerve stimulation therapy for the treatment of epilepsy and depression.